Andrea Arruda

This study profiles circulating hematopoietic stem and progenitor cells in MPN patients, identifying transcriptional signatures and quantitative readouts to distinguish MF from other MPNs and predict progression.

This study shows that PLK1 inhibition eradicates quiescent leukemia stem cells through a non-canonical mechanism involving microtubule and endolysosomal disruption, distinct from its canonical mitotic function.

This study identifies CD59 as a critical regulator of Ras-MAPK signaling in AML, showing its depletion impairs leukemic growth and identifies rILYd4 as a potential therapeutic target.

This study reassesses human mitochondrial DNA methylation using multiple platforms and finds signals likely due to technical artifacts rather than biological methylation.

This study identifies DNA methylation instability in blood cells linked to aging and disease, showing age-related instability and associations with cardiovascular disease and cancer.

This study investigates how DNMT3A-R882 mutations affect HSC differentiation into immune cells, finding they drive dysfunctional neutropoiesis linked to immune dysregulation and inflammatory disease risk.

This study identifies MECOM's role in blocking differentiation via CEBPA repression, showing that targeting this regulatory element can promote differentiation and reduce leukemia burden in AMLs.

The paper constructs a reference atlas of human hematopoiesis and maps AML differentiation patterns, revealing genetic and non-genetic factors driving aberrant differentiation in leukemia.

This study shows FLT3 is essential for ITD-mutated leukemic stem cells but not for normal hematopoietic stem cells, supporting targeted therapies for AML.

SmMIP-tools processes and analyzes smMIP-derived sequencing data, enabling accurate variant detection and improving accessibility to smMIP technology for genetic research.